| 694- | EGCG, | Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways |
| - | in-vitro, | BC, | MCF-7 |
| 693- | EGCG, | CAP, | Phen, | Metabolite modulation of HeLa cell response to ENOX2 inhibitors EGCG and phenoxodiol |
| - | in-vitro, | Cerv, | HeLa |
| 692- | EGCG, | EGCG: The antioxidant powerhouse in lung cancer management and chemotherapy enhancement |
| - | Review, | NA, | NA |
| 691- | EGCG, | Preclinical Pharmacological Activities of Epigallocatechin-3-gallate in Signaling Pathways: An Update on Cancer |
| - | Review, | NA, | NA |
| 690- | EGCG, | Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer |
| - | in-vitro, | Pca, | NA |
| 689- | EGCG, | EGCG inhibited bladder cancer SW780 cell proliferation and migration both in vitro and in vivo via down regulation of NF-κB and MMP-9 |
| - | vitro+vivo, | Bladder, | SW780 |
| - | in-vitro, | PC, | NA |
| 687- | EGCG, | Estrogen receptor-α36 is involved in epigallocatechin-3-gallate induced growth inhibition of ER-negative breast cancer stem/progenitor cells |
| - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | MDA-MB-468 |
| 686- | EGCG, | Prevention effect of EGCG in rat's lung cancer induced by benzopyrene |
| - | in-vivo, | Lung, | NA |
| 685- | EGCG, | CUR, | SFN, | RES, | GEN | The “Big Five” Phytochemicals Targeting Cancer Stem Cells: Curcumin, EGCG, Sulforaphane, Resveratrol and Genistein |
| - | Analysis, | NA, | NA |
| 683- | EGCG, | Targeting the AMP-Activated Protein Kinase for Cancer Prevention and Therapy |
| - | Review, | NA, | NA |
| 684- | EGCG, | Improving the anti-tumor effect of EGCG in colorectal cancer cells by blocking EGCG-induced YAP activation |
| - | in-vitro, | CRC, | NA |
| 675- | EGCG, | When Natural Compounds Meet Nanotechnology: Nature-Inspired Nanomedicines for Cancer Immunotherapy |
| - | Review, | Var, | NA |
| 676- | EGCG, | Chemo, | The Potential of Epigallocatechin Gallate (EGCG) in Targeting Autophagy for Cancer Treatment: A Narrative Review |
| - | Review, | NA, | NA |
| 677- | EGCG, | Induction of Endoplasmic Reticulum Stress Pathway by Green Tea Epigallocatechin-3-Gallate (EGCG) in Colorectal Cancer Cells: Activation of PERK/p-eIF2 α /ATF4 and IRE1 α |
| - | in-vitro, | CRC, | HT-29 |
| 678- | EGCG, | Cancer Prevention with Green Tea and Its Principal Constituent, EGCG: from Early Investigations to Current Focus on Human Cancer Stem Cells |
| 679- | EGCG, | 5-FU, | Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer |
| - | in-vitro, | CRC, | NA |
| 680- | EGCG, | Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea |
| - | Review, | NA, | NA |
| 681- | EGCG, | Suppressing glucose metabolism with epigallocatechin-3-gallate (EGCG) reduces breast cancer cell growth in preclinical models |
| - | vitro+vivo, | BC, | NA |
| 682- | EGCG, | Suppressive Effects of EGCG on Cervical Cancer |
| - | Review, | NA, | NA |
| 3428- | EGCG, | Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex |
| - | Review, | Var, | NA |
| 3230- | EGCG, | Green Tea Polyphenol Epigallocatechin 3-Gallate, Contributes to the Degradation of DNMT3A and HDAC3 in HCT 116 Human Colon Cancer Cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 |
| 3229- | EGCG, | Epigallocatechin-3-gallate (EGCG) Alters Histone Acetylation and Methylation and Impacts Chromatin Architecture Profile in Human Endothelial Cells |
| - | in-vitro, | Nor, | HMEC | - | in-vitro, | Nor, | HUVECs |
| 3228- | EGCG, | Targeting fibrotic signaling pathways by EGCG as a therapeutic strategy for uterine fibroids |
| 3227- | EGCG, | Epigallocatechin-3-gallate treatment to promote neuroprotection and functional recovery after nervous system injury |
| - | NA, | Nor, | NA |
| 3226- | EGCG, | Epigallocatechin-3-gallate, a green-tea polyphenol, suppresses Rho signaling in TWNT-4 human hepatic stellate cells |
| - | in-vitro, | Nor, | NA |
| 3225- | EGCG, | Epigallocatechin‐3‐Gallate Ameliorates Diabetic Kidney Disease by Inhibiting the TXNIP/NLRP3/IL‐1β Signaling Pathway |
| - | in-vitro, | Nor, | NA | - | in-vivo, | Nor, | NA |
| 3224- | EGCG, | Epigallocatechin-3-Gallate Prevents Acute Gout by Suppressing NLRP3 Inflammasome Activation and Mitochondrial DNA Synthesis |
| - | in-vitro, | Nor, | NA |
| 3223- | EGCG, | The Effects of Green Tea Catechins in Hematological Malignancies |
| - | Review, | AML, | NA |
| 3222- | EGCG, | Epigallocatechin gallate and mitochondria—A story of life and death |
| - | Review, | Nor, | NA |
| 3217- | EGCG, | Epigallocatechin-3-gallate promotes angiogenesis via up-regulation of Nfr2 signaling pathway in a mouse model of ischemic stroke |
| - | in-vivo, | Stroke, | NA |
| 3221- | EGCG, | EGCG upregulates phase-2 detoxifying and antioxidant enzymes via the Nrf2 signaling pathway in human breast epithelial cells |
| - | in-vitro, | Nor, | MCF10 |
| 3220- | EGCG, | Dual Roles of Nrf2 in Cancer |
| - | in-vitro, | Lung, | A549 |
| 3219- | EGCG, | Nano-chemotherapeutic efficacy of (−) -epigallocatechin 3-gallate mediating apoptosis in A549 cells: Involvement of reactive oxygen species mediated Nrf2/Keap1signaling |
| - | in-vitro, | Lung, | A549 |
| 3218- | EGCG, | Comparative efficacy of epigallocatechin-3-gallate against H2O2-induced ROS in cervical cancer biopsies and HeLa cell lines |
| - | in-vitro, | Cerv, | HeLa |
| 3241- | EGCG, | Epigallocatechin gallate triggers apoptosis by suppressing de novo lipogenesis in colorectal carcinoma cells |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HT29 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Liver, | HUH7 |
| 3231- | EGCG, | Epigallocatechin-3-gallate restores mitochondrial homeostasis impairment by inhibiting HDAC1-mediated NRF1 histone deacetylation in cardiac hypertrophy |
| - | in-vitro, | Nor, | NA |
| 3232- | EGCG, | (−)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer׳s disease model mice by upregulating neprilysin expression |
| - | in-vivo, | AD, | NA |
| 3233- | EGCG, | Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways |
| - | in-vitro, | Cerv, | HeLa |
| 3234- | EGCG, | Rad, | EGCG, a tea polyphenol, as a potential mitigator of hematopoietic radiation injury in mice |
| - | in-vivo, | Nor, | NA |
| 3235- | EGCG, | (-)-Epigallocatechin-3-gallate reverses the expression of various tumor-suppressor genes by inhibiting DNA methyltransferases and histone deacetylases in human cervical cancer cells |
| - | in-vivo, | Cerv, | HeLa |
| 3236- | EGCG, | Buty, | Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate |
| - | in-vitro, | Colon, | RKO | - | in-vitro, | Colon, | HCT116 | - | in-vitro, | Colon, | HT29 |
| 3237- | EGCG, | (-)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer's disease model mice by upregulating neprilysin expression |
| - | in-vivo, | AD, | NA |
| 3238- | EGCG, | Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications |
| - | Review, | Var, | NA |
| 3239- | EGCG, | (−)-Epigallocatechin Gallate, A Major Constituent of Green Tea, Poisons Human Type II Topoisomerases |
| - | in-vitro, | AML, | K562 |
| 3242- | EGCG, | Epigallocatechin gallate has pleiotropic effects on transmembrane signaling by altering the embedding of transmembrane domains |
| 3243- | EGCG, | (−)-Epigallocatechin-3-Gallate Inhibits Colorectal Cancer Stem Cells by Suppressing Wnt/β-Catenin Pathway |
| 3244- | EGCG, | Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells |
| 3245- | EGCG, | (−)-Epigallocatechin-3-gallate protects PC12 cells against corticosterone-induced neurotoxicity via the hedgehog signaling pathway |
| - | in-vitro, | Nor, | PC12 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid